ImmunityBio, Inc.

ImmunityBio, Inc. is a U.S. biotechnology company developing and commercializing immunotherapies that activate both the innate and adaptive immune systems. Its core platform centers on ANKTIVA® (nogapendekin alfa inbakicept) and a broader Cancer BioShield portfolio that includes NK-cell therapies, adenovirus-vectored vaccines, and other immunomodulators aimed at cancer and infectious disease.

−212,3 %

99,3 %

−310,2 %

+668,3 %

5.10

5.08

— ImmunityBio, Inc.
%
Commercial immunotherapy55% Approved and marketed oncology immunotherapy centered on ANKTIVA for commercial use.
Clinical-stage pipeline25% Development programs including NK-cell therapies, vaccines, and other immunomodulators.
Licensing and IP programs10% Non-exclusive license agreements and licensed technology monetization.
Bioprocessing products10% Sale of bioreactors and related consumables used in research and manufacturing.

ImmunityBio sells primarily to healthcare providers and institutions that administer oncology therapies, including...

  • Oncology treatment centersprimary

    Clinics, hospitals, and infusion centers that buy ANKTIVA to treat eligible cancer patients and need specialty distribution support.

  • Specialty pharmacy and distributorsprimary

    Channel partners that handle stocking and delivery of the approved product into care settings.

  • Government and institutional buyerssecondary

    Public-sector and institutional purchasers that access the commercial product through contracted specialty channels.

  • Licensing counterpartiessecondary

    Partners that license cell lines, know-how, or other intellectual property and generate non-product revenue.

  • Bioprocessing customersemerging

    Customers buying bioreactors and consumables for research, development, or manufacturing use.

The company is headquartered in the United States and its current commercial buildout is centered there, including...

  • •United States is the core market for approved ANKTIVA commercialization
  • •Dunkirk, New York is a key manufacturing and scale-up location
  • •EU and UK are targeted for clinical expansion of ResQ201A
  • •Canada and Asia are planned next-step trial and market expansion regions
  • •Global expansion increases regulatory and supply-chain complexity

ImmunityBio is building a commercial oncology franchise around ANKTIVA while advancing a broader universal Cancer...

01
Grow ANKTIVA commercial adoptionshort-term

The approved product is the main near-term revenue driver and validates the platform.

02
Strengthen manufacturing resiliencemedium-term

Commercial supply and future pipeline launches depend on reliable, scalable production.

03
Advance pipeline beyond ANKTIVAmedium-term

Long-term value depends on converting the broader platform into additional approved products.

The company remains highly dependent on a single approved product while most of its pipeline is still clinical-stage,...

high

Dependence on a single approved product

The company has one commercial product and a broad clinical pipeline, so any setback in ANKTIVA uptake would materially affect revenue and credibility.

Scope
Commercial oncology franchise
Materiality
high
high

Need for additional financing

Commercialization, manufacturing buildout, and clinical trials require substantial cash before the business reaches durable scale.

Scope
Operating funding and dilution
Materiality
high
high

Manufacturing and supply constraints

Shelf life, comparability, and facility obligations can affect product availability and delay changes in production sources.

Scope
ANKTIVA supply and future product launches
Materiality
high
high

Regulatory and clinical development risk

Pipeline programs require successful trials and approvals in multiple jurisdictions, which may not be achieved on schedule or at all.

Scope
U.S., EU, UK, Canada, Asia
Materiality
high
medium

Intellectual property and licensing obligations

The company relies on licensed technology and may owe milestones and royalties that reduce economics.

Scope
GlobeImmune and other IP arrangements
Materiality
medium
medium

Cybersecurity and third-party operational risk

Clinical, manufacturing, and shared-service systems depend on external vendors and are exposed to cyberattacks and outages.

Scope
CROs, CMOs, clinical sites, shared services
Materiality
medium
Revenue recognition and sales deductions
Can materially affect quarterly revenue and gross-to-net trends
Contingent milestone and royalty obligations
Affects liabilities, cash flow, and long-term product economics
Lease and facility commitments
Creates significant future cash obligations and execution risk
Estimates and assumptions in a clinical-stage biotech
Can cause meaningful period-to-period changes in reported results

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

ANAPTYSBIO, INC

ANAB · Pharmaceutical Preparations

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

IN8BIO, INC.

INAB · Biological Products, (No Diagnostic Substances)

IMMUCELL CORP /DE/

ICCC · In Vitro & In Vivo Diagnostic Substances

: 28.4.2026